Wegovy (semaglutide 2.4mg) and Mounjaro (tirzepatide) are the most-prescribed weight-loss shots. Wegovy averages 14.9%; Mounjaro pushes toward 22.5%. Same weekly ritual, same food framework — Mounjaro just leaves less room for error.
| A | B | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Average weight loss | 14.9% (STEP 1) | Up to 22.5% (SURMOUNT-1) |
| Dosing | Weekly | Weekly |
| Muscle-loss risk | Significant | Higher |
| Food rules | Protein-first framework | Same, stricter |
The same judgment framework runs across this site — protein, fiber and how heavy a food sits on a slow stomach.
| Easy on both | Risky on both |
|---|---|
|
|
Both are in the same class and both slow the stomach; nausea is dose-dependent and individual. The management is identical: small, bland, low-fat meals in the days after the shot.
No — same framework, higher stakes. Protein-first and small meals matter slightly more because the appetite suppression is stronger.
The dual GIP+GLP-1 action amplifies appetite suppression beyond GLP-1 alone. Clinically that is roughly 5-7 more percentage points of loss.
This comparison presents published trial data (STEP, SURMOUNT, SCALE, OASIS 4) and FDA label information for reference. It is not medical advice and does not recommend any medication. Prescription decisions belong to you and your healthcare provider.